Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan.

A tumor-naive plasma-only assay was used to call molecular residual disease in 80 people with stage II or III colorectal cancer selected from the GALAXY study. The abstract does not name the product.

Clinical Cancer ResearchPubMed 39513962DOI 10.1158/1078-0432.CCR-24-2396